⚠️ NOT FOR HUMAN CONSUMPTION – FOR RESEARCH PURPOSES ONLY ⚠️ AOD‑9604A synthetic 16‑amino acid peptide analogue derived from the C-terminal fragment (hGH 177–191) of human growth hormone, developed for its potential lipolytic (fat breakdown) and anti‑lipogenic (fat formation suppression) properties without stimulating IGF‑1. Form: Lyophilized powder Purity: >98% (HPLC) Storage: Store in a cool, dry, and dark place; long-term storage typically at –20 °C(Sources: Wikipedia – AOD‑9604, DrugBank overview) Research Highlights Induces selective lipolysis in adipose tissue without affecting glucose metabolism or insulin sensitivity, distinguishing it from full-length hGH in animal models(Source: Horm Res – preclinical obesity study) In a 12-week human clinical trial, participants receiving AOD‑9604 lost an average of 2.6 kg compared to 0.8 kg in the placebo group; however, subsequent longer-term trials did not demonstrate significant weight-loss effects, which led to discontinuation of its development(Source: PMC obesity pharmacotherapy review) Research suggests lipolysis occurs independently of IGF‑1 elevation, reinforcing its targeted mechanism of action in fat tissue(Sources: Journal of Endocrinology & Metabolism – safety data, Wikipedia summary on mechanism and trials) This compound is strictly intended for laboratory research use only.It is not approved for human or veterinary use, not a dietary supplement, and must not be used to diagnose, treat, cure, or prevent any disease or condition. FOR LABORATORY USE ONLY. NOT FOR HUMAN CONSUMPTION.